{"organizations": [], "uuid": "419598bdda2dce6bbfbf6ba40975b7ec8b8192df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-audentes-announces-data-from-first/brief-audentes-announces-data-from-first-dose-cohort-of-aspiro-idUSASC0A2NC", "country": "US", "domain_rank": 408, "title": "BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.053, "site_type": "news", "published": "2018-05-16T23:56:00.000+03:00", "replies_count": 0, "uuid": "419598bdda2dce6bbfbf6ba40975b7ec8b8192df"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-audentes-announces-data-from-first/brief-audentes-announces-data-from-first-dose-cohort-of-aspiro-idUSASC0A2NC", "ord_in_thread": 0, "title": "BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO", "locations": [], "entities": {"persons": [], "locations": [{"name": "aspiro", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "audentes therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Audentes Therapeutics Inc:\n* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY\n* PATIENT 1 HAS ACHIEVED VENTILATOR INDEPENDENCE AND ORAL FEEDING\n* SIGNIFICANT IMPROVEMENTS IN NEUROMUSCULAR AND RESPIRATORY FUNCTION AT 24-WEEK TIMEPOINT\n* HAVE BEEN TOTAL OF 24 ADVERSE EVENTS REPORTED IN ASPIRO, SIX OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS\n* THERE HAVE BEEN AN ADDITIONAL 11 NON-SERIOUS AES IN ASPIRO, ALL DETERMINED TO BE NOT TREATMENT-RELATED Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T23:56:00.000+03:00", "crawled": "2018-05-17T14:38:44.068+03:00", "highlightTitle": ""}